Inovio Pharmaceuticals, INC 10-Q quarterly reports

Inovio Pharmaceuticals reported a net loss of $19.7 million for Q1 2026, while facing FDA review challenges for its lead drug candidate, INO-3107.

Inovio Pharmaceuticals reported significant net losses for Q3 2025, with cash reserves projected to last only into Q2 2026, raising substantial doubt about its ability to continue as a going concern.

Inovio Pharmaceuticals reported continued significant losses and expressed substantial doubt about its ability to continue as a going concern beyond Q2 2026, despite recent capital raises.

Inovio Pharmaceuticals reports a net loss of $19.7 million for Q1 2025 and anticipates current resources will fund operations into Q1 2026.

Inovio Pharmaceuticals' Q3 2024 report reveals a net loss of $25.2 million and a delay in BLA submission for INO-3107 due to a manufacturing issue.

Inovio Pharmaceuticals reported a net loss of $32.2 million for the second quarter of 2024 and provided updates on its clinical programs, including a delay in the BLA submission for INO-3107.

Inovio Pharmaceuticals reported a net loss of $30.5 million for the first quarter of 2024, while highlighting progress in its clinical programs and a recent capital raise.